Tuberculosis bacteria hide from drugs by pausing growth in acid

Treating tuberculosis is complicated because Mycobacterium tuberculosis (Mtb) can change how it grows in response to conditions inside the body, helping it survive both immune attack and drug treatment. Researchers led by Bree B. Aldridge set out to understand those changes at the single-cell level, asking whether the whole bacterial population slows down or whether some cells take a different approach. Rather than finding a uniform slowdown, they discovered that Mtb responds to acidic environments by increasing the proportion of individual bacteria that enter a growth-arrested state. In other words, the population doesn’t all slow a little; more cells stop growing entirely. This shift was not a rare laboratory artifact: clinical strains showed higher numbers of these non-growing cells under both neutral and acidic conditions. The study reframes how we think about bacterial survival strategies during infection, moving from a picture of uniform stress response to one of deliberate diversification within the population.

To reveal these patterns, the team examined behavior at the single-cell level and compared responses between laboratory and clinical strains of Mtb exposed to acidic environments. Their key finding was that acid adaptation increases the proportion of bacteria in a growth-arrested state rather than simply reducing the growth rate across the board. Importantly, this non-growing subpopulation proved more tolerant to the drug ethambutol, demonstrating a clear link between growth arrest and treatment survival. The researchers also investigated genetic control of this state and found that the PhoPR two-component system contributes to regulating the non-growing subpopulation, but only partially: other transcriptional regulators are clearly involved. By showing that growth arrest is an active, regulated response and not just a passive consequence of stress, the study highlights specific biological players and conditions that matter for drug tolerance.

These results matter because they show a concrete way Mtb can survive drug exposure and immune stress by diversifying its population. Calling this behavior a bet-hedging strategy, the work suggests that some bacteria intentionally enter a protected, non-growing state to improve overall survival during infection. For clinicians and drug developers, the finding that non-growing cells are more tolerant to ethambutol and are actively regulated implies that effective therapies may need to account for subpopulations, not just average growth rates. It also points to the PhoPR two-component system and other, unidentified transcriptional regulators as potential targets for future research aimed at preventing growth arrest or sensitizing non-growing cells to drugs. Overall, the study argues that understanding and targeting these non-growing subpopulations could be essential for reducing treatment survival and improving tuberculosis outcomes.